Motus GI Holdings's Days Sales Outstanding for the
three
months ended in Mar. 2024 was 111.92.
Motus GI Holdings's Days Inventory for the
three
months ended in Mar. 2024 was 1798.39.
Motus GI Holdings's Days Payable for the
three
months ended in Mar. 2024 was 0.
Therefore, Motus GI Holdings's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2024 was 1,910.31.
Motus GI Holdings (OTCPK:MOTS) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Motus GI Holdings Cash Conversion Cycle Related Terms
Motus GI Holdings Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Motus GI Holdings's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MOTS vs ABT, BSX, SYK: Cash Conversion Cycle Comparison
For the Medical Devices subindustry, Motus GI Holdings's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Motus GI Holdings Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Motus GI Holdings's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Motus GI Holdings's Cash Conversion Cycle falls into.
Motus GI Holdings Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Motus GI Holdings's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Conversion Cycle of 1,910.31 mean?
Motus GI Holdings (MOTS) has a Cash Conversion Cycle of 1,910.31 as of Mar. 2024. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Motus GI Holdings and its competitors.
Is Motus GI Holdings' Cash Conversion Cycle too high?
Motus GI Holdings' current Cash Conversion Cycle is 1,910.31. The Medical Devices & Instruments industry median Cash Conversion Cycle is 156.39. Motus GI Holdings' value of 1,910.31 is 1121.5% above this industry median. Overall, Motus GI Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Motus GI Holdings' Cash Conversion Cycle compare to ABT and BSX?
Motus GI Holdings' Cash Conversion Cycle of 1,910.31 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 156.39. Motus GI Holdings' value of 1,910.31 is 1121.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 156.39, based on 818 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Motus GI Holdings's current Cash Conversion Cycle of 1,910.31 is 1121.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Motus GI Holdings and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 156.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Motus GI Holdings's current Cash Conversion Cycle is 1,910.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Motus GI Holdings stock overvalued right now?
Motus GI Holdings (MOTS) has a current Cash Conversion Cycle of 1,910.31. The current Cash Conversion Cycle is 1,910.31 and 1121.5% above the Medical Devices & Instruments industry median of 156.39. Motus GI Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Motus GI Holdings (MOTS), the current Cash Conversion Cycle is 1,910.31 as of Mar. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Motus GI Holdings Inc is a medical technology company dedicated to improving endoscopy outcomes, lowering costs, and enhancing patient experiences. The company has developed the Pure-Vu System, a medical device that has been cleared by the U.S. Food and Drug Administration (the FDA) to help facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and to help facilitate upper gastrointestinal (GI) endoscopy procedures. The Pure-Vu System is also CE marked in the European Economic Area (EEA) for use in colonoscopy.
12GF Score
Get the complete analysis for MOTS
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MOTS has been successfully added to your 
